Literature DB >> 7814480

Determination of parallelism and nonparallelism in bioassay dilution curves.

B D Plikaytis1, P F Holder, L B Pais, S E Maslanka, L L Gheesling, G M Carlone.   

Abstract

There is a lack of consensus among investigators who use a variety of immunoassay techniques (e.g., enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay) regarding the protocols for describing and forming standard reference or calibration curves and interpolating serum antibody concentrations. This confounds the issue of detecting the presence or absence of parallelism between standard reference serum and serially diluted serum sample curves. These curves must be parallel to support the assumption that the antibody-binding characteristics are similar enough to allow the determination of antibody levels in the diluted serum sample. There is no universal and widely adopted strategy for assessing parallelism in bioassays, and without an assurance of parallelism, investigators are not able to calculate reliable estimates for antibody concentrations in serum samples. Furthermore, single-point (dilution) serum assays do not provide information related to parallelism and nonparallelism, and this, too, may lead to considerable error when calculating antibody concentrations. When assay methodology, technique, and precision improve to the extent that standard reference serum and serially diluted serum sample curves are fit with little error, standard analysis of variance techniques are overly sensitive to negligible departures from parallelism. We present a series of guidelines that compose a protocol for assessing parallelism between bioassay dilution curves that are applicable to data derived from ELISAs. These criteria should be applicable, with minor modifications, to most immunoassay experimental situations and, most importantly, are not dependent on the mathematical model used to form the standard reference curve. These guidelines have evolved in our laboratories over the past 4 years during the performance of thousands of ELISAs for antibodies to the capsular polysaccharides of Neisseria meningitidis groups A and C and Haemophilus influenzae type b.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814480      PMCID: PMC264081          DOI: 10.1128/jcm.32.10.2441-2447.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Radioligand Assay.

Authors:  D J Finney
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  Interlaboratory comparison of radioimmunoassay results. Variation produced by different methods of calculation.

Authors:  S L Jeffcoate; R E Das
Journal:  Ann Clin Biochem       Date:  1977-09       Impact factor: 2.057

3.  A versatile method for simultaneous analysis of families of curves.

Authors:  V Guardabasso; P J Munson; D Rodbard
Journal:  FASEB J       Date:  1988-03-01       Impact factor: 5.191

4.  Robust estimation of standard curves for protein molecular weight and linear-duplex DNA base-pair number after gel electrophoresis.

Authors:  B D Plikaytis; G M Carlone; P Edmonds; L W Mayer
Journal:  Anal Biochem       Date:  1986-02-01       Impact factor: 3.365

5.  A new parallelism acceptance criterion for validating large plate bioassay results.

Authors:  M J Story; J A Winson; P L Beyer; G Boehm
Journal:  J Biol Stand       Date:  1986-07

Review 6.  Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays.

Authors:  D Rodbard
Journal:  Clin Chem       Date:  1974-10       Impact factor: 8.327

7.  The effect of data reduction technic on ligand assay proficiency survey results.

Authors:  P J Pegg; E M Miner
Journal:  Am J Clin Pathol       Date:  1982-03       Impact factor: 2.493

8.  An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay.

Authors:  D C Phipps; J West; R Eby; M Koster; D V Madore; S A Quataert
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

9.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

10.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

View more
  42 in total

1.  Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies.

Authors:  Sandra Romero-Steiner; Tamar Pilishvili; Jacquelyn S Sampson; Scott E Johnson; Annie Stinson; George M Carlone; Edwin W Ades
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

2.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study.

Authors:  B D Plikaytis; D Goldblatt; C E Frasch; C Blondeau; M J Bybel; G S Giebink; I Jonsdottir; H Käyhty; H B Konradsen; D V Madore; M H Nahm; C A Schulman; P F Holder; T Lezhava; C M Elie; G M Carlone
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.

Authors:  Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 5.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

6.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

7.  Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Authors:  Henry C Baggett; Thomas W Hennessy; Lisa Bulkow; Sandra Romero-Steiner; Debra Hurlburt; Patricia Holder; Alan J Parkinson; Rosalyn J Singleton; Orin Levine; George M Carlone; Jay C Butler
Journal:  Clin Vaccine Immunol       Date:  2006-06

8.  Key elements of bioanalytical method validation for macromolecules.

Authors:  Marian Kelley; Binodh DeSilva
Journal:  AAPS J       Date:  2007-05-18       Impact factor: 4.009

9.  Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Carla W A M Engels; Ger T Rijkers; Elisabeth A Sanders; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

10.  Robust Non-inferiority Tests for Potency of a Test Drug Against a Reference Drug: (To appear in Statistics in Biopharmaceutical Research ).

Authors:  Michael P Fay; Farzad Noubary; Allan Saul
Journal:  Stat Biopharm Res       Date:  2009-08-01       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.